Transcatheter Tricuspid Valve Intervention: Coaptation Devices

Frontiers in Cardiovascular Medicine

article

Guillem Muntané-Carol¹  Alberto Alperi¹  Laurent Faroux¹  Elisabeth Bédard¹  François Philippon¹  Josep Rodés-Cabau¹ 

[1] Quebec Heart and Lung Institute, Laval University

关键词: tricuspid regurgitation (TR);    transcatheter tricuspid intervention;    FORMA;    PASCAL;    MitraClip device;   

DOI  :  10.3389/fcvm.2020.00139

学科分类：地球科学(综合)

来源: Frontiers

【 摘 要 】

Transcatheter tricuspid valve intervention (TTVI) has recently emerged as an alternative for the treatment of severe tricuspid regurgitation (TR). Multiple percutaneous devices have been developed in the last decade with promising early results. Among them, the coaptation devices are designed to reduce TR severity by valve leaflet plication or occupying the regurgitant orifice with a spacer. To date, the MitraClip/TriClip devices (Abbott, Santa Clara, CA, USA), the PASCAL system (Edwards Lifesciencies, Irvine, CA, USA), and the FORMA device (Edwards Lifesciencies, Irvine, CA, USA) have been used as coaptation devices for treating severe TR. The present document aimed to review the clinical evidence on coaptation devices in the field of TTVI, describing its design characteristics, main procedural steps, and early and mid-term outcomes.

【 授权许可】

CC BY